![Kristen Quigley](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kristen Quigley
Direttore operativo presso MOLECULAR TEMPLATES, INC.
Posizioni attive di Kristen Quigley
Società | Posizione | Inizio | Fine |
---|---|---|---|
MOLECULAR TEMPLATES, INC. | Direttore operativo | 02/08/2023 | - |
Corporate Officer/Principal | 01/01/2017 | 02/08/2023 |
Storia della carriera di Kristen Quigley
Precedenti posizioni note di Kristen Quigley
Società | Posizione | Inizio | Fine |
---|---|---|---|
Threshold Pharmaceuticals, Inc.
![]() Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Direttore operativo | - | - |
Formazione di Kristen Quigley
Washington University in St. Louis | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Posizioni
Chief Operating Officer | 2 |
Undergraduate Degree | 1 |
Corporate Officer/Principal | 1 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
Aziende private | 1 |
---|---|
Threshold Pharmaceuticals, Inc.
![]() Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
- Borsa valori
- Insiders
- Kristen Quigley
- Esperienza